Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-122 plus R-CHOP-21 in previously untreated poor-risk diffuse large B-cell lymphoma
2016-003778-42Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avadomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Celgene Corporation. Primary endpoint: Maximum Tolerated Dose/Maximum Administered Dose. Started May 2017; status: completed.
02
Drugs
avadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2016-003778-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003778-42.